# Local Consolidative Therapy and Brigatinib in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer

> **NCT03707938** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **M.D. Anderson Cancer Center** · enrollment: 35 (actual)

## Conditions studied

- Advanced Lung Carcinoma
- ALK Gene Rearrangement
- Lung Non-Small Cell Carcinoma
- Recurrent Lung Non-Small Cell Carcinoma
- Stage IV Lung Cancer AJCC v8
- Stage IVA Lung Cancer AJCC v8
- Stage IVB Lung Cancer AJCC v8

## Interventions

- **DRUG:** Brigatinib
- **PROCEDURE:** Local Consolidation Therapy

## Key facts

- **NCT ID:** NCT03707938
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2018-12-18
- **Primary completion:** 2026-01-28
- **Final completion:** 2026-01-28
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2025-11-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03707938

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03707938, "Local Consolidative Therapy and Brigatinib in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03707938. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*